Get the Stockscreener App
62.56
2.07%
-1.32
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $62.56, with a volume of 4.54M.
It is down -2.07% in the last 24 hours and down -19.08% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$63.88
Open:
$64.42
24h Volume:
4.54M
Relative Volume:
2.48
Market Cap:
$30.51B
Revenue:
$10.40B
Net Income/Loss:
$980.00M
P/E Ratio:
31.68
EPS:
1.9749
Net Cash Flow:
$1.61B
1W Performance:
-15.56%
1M Performance:
-19.08%
6M Performance:
-15.43%
1Y Performance:
-34.75%
1-Day Range:
$62.40
$64.82
1-Week Range:
$62.40
$74.82
52-Week Range:
$62.40
$96.88
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC vs ISRG, BDX, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
62.56 | 30.51B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
450.06 | 159.39B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.43 | 41.17B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
39.52 | 33.42B | 29.14B | 1.07B | 1.52B | 1.1995 |
RMD
Resmed Inc
|
206.76 | 29.99B | 5.54B | 1.52B | 1.74B | 10.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jan-20-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-09-26 | Downgrade | Stifel | Buy → Hold |
| Dec-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Alcon declines 10% after Q1 revenue misses consensus - MSN
Free float of ALCON N 2.LINIE – SIX:ALCE - TradingView
Return on assets % of ALCON N 2.LINIE – SIX:ALCE - TradingView
Alcon Inc. stock (CH0432492467): Eye care giant eyes growth in contact lenses and surgery devices - AD HOC NEWS
Enterprise value of ALCON N 2.LINIE – SIX:ALCE - TradingView
ALCON N 2.LINIE Cash Flow – SIX:ALCE - TradingView
Alcon Inc stock (CH0432492467): Eye care specialist reports mixed Q1 results and updates outlook - AD HOC NEWS
ALCON N 2.LINIE Statistics – SIX:ALCE - TradingView
ALCON N 2.LINIE Balance Sheet – SIX:ALCE - TradingView
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX) - The Globe and Mail
Number of shareholders of Alcon AG – MIL:1ALC - TradingView
Alcon Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:ALC) 2026-05-08 - Seeking Alpha
Mizuho Securities Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $85 - Moomoo
Alcon Inc. stock (CH0432492467): 10% sales growth and $1.5B buyback lift shares - AD HOC NEWS
LENSAR signals 2027 as really, really good year as it rebuilds distributor orders after Alcon deal termination - MSN
Tranche Update on Alcon Inc.'s Equity Buyback Plan announced on February 25, 2025. - marketscreener.com
Needham tracks April prescription trends for Alcon and Bausch + Lomb eye drugs - Investing.com Canada
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $110.2 - Moomoo
Bernstein Keeps Alcon at Outperform After Q1 Results; Estimates, Price Target Revised - Moomoo
Alcon Inc stock (CH0432492467): Eye care specialist eyes growth in contact lenses and surgery device - AD HOC NEWS
Alcon (ALC) Gets a Buy from RBC Capital - The Globe and Mail
ALC Maintains Overweight Rating -- Price Target Lowered to $86.0 - GuruFocus
ALC Maintains Rating by Baird -- Price Target Lowered to $90 - GuruFocus
ALC Maintains by Mizuho -- Price Target Lowered to $85.00 - GuruFocus
Here's why Alcon (ALC) is a strong value stock - MSN
Fewer cataract surgeries slow Alcon - WFMZ.com
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $70.65 to $102.76 - Moomoo
Here's Why Alcon (ALC) is a Strong Value Stock - Yahoo Finance
Alcon forecasts 5%-7% sales growth and announces $1.5B share repurchase program amid reduced tariff assumption - MSN
Alcon Reports First Quarter Growth Boosted by New Product Launches - VisionMonday.com
Needham Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $95 - Moomoo
Alcon Q1 2026 Sales Rise 10% as New Eye-Care Products Power Growth and $1.5 Billion Buyback - The Globe and Mail
Alcon: Results weren't bad; today's correction is a buying opportunity - marketscreener.com
Alcon (ALC) Q1 2026 Earnings Call Transcript - AOL.com
BTIG lowers Alcon stock price target to $82 on lower valuation - Investing.com UK
BTIG lowers Alcon stock price target to $82 on lower valuation By Investing.com - Investing.com Australia
Alcon stock slides as Q1 sales miss expectations and reported profitability drops sharply - Quiver Quantitative
Alcon Kicks Off 2026 on Solid Results as New Innovations Pay Dividends - Morningstar
Alcon Q1 2026 Earnings Call Transcript - Benzinga
Alcon Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
BofA Securities Maintains Alcon(ALC.US) With Sell Rating, Cuts Target Price to $70.38 - Moomoo
Swiss eye care firm Alcon’s quarterly revenue rises less than expected - WHTC
Alcon slides after revenue misses forecasts, operating profit falls sharply By Investing.com - Investing.com Canada
Alcon slides after revenue misses forecasts, operating profit falls sharply - Investing.com
Needham Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Alcon shares see BofA reiterate underperform on soft Q1 results By Investing.com - Investing.com India
Alcon shares see BofA reiterate underperform on soft Q1 results - Investing.com UK
I ricavi trimestrali dell'azienda svizzera Alcon, specializzata nella cura degli occhi, crescono meno del previsto - TradingView
Alcon Price Target Declines as AlphaValue/Baader Cuts Estimates on Rising Competition, Expenses - marketscreener.com
Earnings Preview: Alcon to Report Financial Results Pre-market on May 06 - Moomoo
Alcon Logs Lower Q1 Net Income; Net Sales, Other Revenue Rise - marketscreener.com
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):